In addition, JMJD5 overexpression combined with gefitinib significantly reduced EGFR expression and suppressed the growth of gefitinib-resistant NSCLC in xenograft mouse models (Fig. 6I, J, Fig. S5A, B). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.